Clinical Trial

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-07
Trial Details
NCT Number NCT07389590
Lead Sponsor Johns Hopkins University
Collaborators: TG Therapeutics, Inc.
Conditions Multiple Sclerosis
Enrollment 50 participants
Start Date 2026-02-10
Primary Completion 2028-10 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-06